Evidence map›Paper›PMID 34054813›Full record

ArticleFrontiers in immunology2021

Peroxiredoxin 3 Inhibits Acetaminophen-Induced Liver Pyroptosis Through the Regulation of Mitochondrial ROS.

Yue Wang, Yan Zhao, Zhecheng Wang, Ruimin Sun, Boyang Zou, Ruixi Li, Deshun Liu, Musen Lin, Junjun Zhou, Shili Ning and 2 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Food science & nutrition · 2024
    Article
  15. Article
  16. Article
  17. NLRP3 Inflammasome in Acute and Chronic Liver Diseases.International journal of molecular sciences · 2024
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yue WangDepartment of Pharmacology, Dalian Medical University, Dalian, China.
Yan ZhaoDepartment of Pharmacology, Dalian Medical University, Dalian, China.
Zhecheng WangDepartment of Pharmacology, Dalian Medical University, Dalian, China.
Ruimin SunDepartment of Pharmacology, Dalian Medical University, Dalian, China.
Boyang ZouDepartment of Pharmacology, Dalian Medical University, Dalian, China.
Ruixi LiDepartment of Pharmacology, Dalian Medical University, Dalian, China.
Deshun LiuDepartment of General Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Musen LinDepartment of Pharmacy, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Junjun ZhouDepartment of Pharmacology, Dalian Medical University, Dalian, China.
Shili NingDepartment of General Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Xiaofeng TianDepartment of General Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Jihong YaoDepartment of Pharmacology, Dalian Medical University, Dalian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pyroptosis is a newly discovered form of cell death. Peroxiredoxin 3 (PRX3) plays a crucial role in scavenging reactive oxygen species (ROS), but its hepatoprotective capacity in acetaminophen (APAP)-induced liver disease remains unclear. The aim of this study was to assess the role of PRX3 in the regulation of pyroptosis during APAP-mediated hepatotoxicity. We demonstrated that pyroptosis occurs in APAP-induced liver injury accompanied by intense oxidative stress and inflammation, and liver specific PRX3 silencing aggravated the initiation of pyroptosis and liver injury after APAP intervention. Notably, excessive mitochondrial ROS (mtROS) was observed to trigger pyroptosis by activating the NLRP3 inflammasome, which was ameliorated by Mito-TEMPO treatment, indicating that the anti-pyroptotic role of PRX3 relies on its powerful ability to regulate mtROS. Overall, PRX3 regulates NLRP3-dependent pyroptosis in APAP-induced liver injury by targeting mitochondrial oxidative stress.

Indexed as

AcetaminophenAnimalsBiomarkersChemical and Drug Induced Liver InjuryGene SilencingHepatocytesImmunohistochemistryInflammasomesLiverMaleMiceMitochondriaModels, BiologicalNLR Family, Pyrin Domain-Containing 3 ProteinPeroxiredoxin IIIPyroptosisAcetaminophenBiomarkersInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinPeroxiredoxin IIIReactive Oxygen SpeciesAPAPmitochondrial ROS (mtROS)NLRP3 inflammasomePRX3pyroptosis

Identifiers

PMID34054813
PMCPMC8155593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.